Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: 38rocket who wrote (3225)	6/4/1998 11:39:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 9523

A split would be nice. They last split 2 for 1, June 30 /1997. Last quarterly report around this time last year was in August, but I heard somewhere that they'd be releasing earnings in July, can anyone confirm when earnings are coming out. Earnings game should be a nice big play but not the only factor for a sharp rise in PFE stock price for the last half of 1998. Besides Viagra, look what's coming up for the rest of this year. - -- Zeldox (ziprasidone), for treatment of psychotic disorders (filed an NDA with the FDA in March 1997). In January 1998, we made supplemental submissions to the FDA resulting in a 90-day extension of the NDA review period. We hope to launch Zeldox in the second half of 1998. - -- Tikosyn (dofetilide), for treatment of a heart rhythm disorder. U.S. and European regulatory filings for this product were submitted in the first quarter of 1998; - -- eletriptan, for treatment of migraine headaches. Regulatory filings for this product are planned in September of 1998; - -- Alond (zopolrestat), for treatment of nervous system, kidney and cardiovascular disorders related to diabetes; - -- voriconazole, for the treatment of fungal infections; and - -- darifenacin, for the treatment of irritable bowel syndrome and urinary urge incontinence. We are also developing new uses or dosages for Norvasc, Zyrtec, Zoloft, Cardura, Zithromax and Trovan. P.S. Trovan has 14 indications, the highest for any one U.S drug ever. PFE is going to rock like a hot biotech stock but with the added value of being the biggest U.S. "big pharma"